Urea Clot Lysis Test for Factor XIII at Chughtai Lab

Urea Clot Lysis Test for Factor XIII Screening at Chughtai Lab

The Urea Clot Lysis test, also known as the Factor XIII screening test, is a specialized qualitative laboratory investigation used to detect a severe deficiency of coagulation Factor XIII (Fibrin Stabilizing Factor). Factor XIII is the terminal enzyme in the coagulation cascade, playing a pivotal role in stabilizing the blood clot. While routine coagulation profiles such as Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) evaluate the initial stages of clot formation, they remain entirely normal in patients with Factor XIII deficiency. Therefore, the Urea Clot Lysis test at Chughtai Lab serves as an essential diagnostic tool for identifying this rare but clinically significant bleeding disorder, ensuring patients across Pakistan receive accurate diagnoses and timely therapeutic interventions.

To understand the clinical importance of this test, it is necessary to understand how blood clots form and stabilize. When a blood vessel is injured, the coagulation cascade is activated, culminating in the conversion of soluble fibrinogen into insoluble fibrin monomers by the enzyme thrombin. These monomers spontaneously polymerize to form a loose, soluble fibrin gel. At this stage, the clot is fragile and highly susceptible to mechanical breakdown and premature enzymatic degradation (fibrinolysis). Factor XIII, activated by thrombin in the presence of calcium ions, functions as a transglutaminase. It catalyzes the formation of covalent peptide bonds between adjacent glutamine and lysine residues in the fibrin chains. This cross-linking process significantly increases the mechanical strength of the clot and renders it insoluble in denaturing agents. In the absence of sufficient Factor XIII (typically when levels fall below 1% to 2% of normal), the fibrin clot remains non-cross-linked and easily dissolves when exposed to chemical agents like 5M urea or 1% monochloroacetic acid.

The diagnostic value of the Urea Clot Lysis test lies in its ability to screen for both congenital and acquired forms of Factor XIII deficiency. Congenital Factor XIII deficiency is a rare autosomal recessive disorder characterized by severe bleeding diathesis, poor wound healing, and recurrent spontaneous abortions. Acquired Factor XIII deficiency can occur due to decreased synthesis (as seen in severe liver disease or inflammatory bowel disease), increased consumption (such as in disseminated intravascular coagulation), or the development of autoantibodies against Factor XIII. By utilizing standardized laboratory protocols and high-quality reagents, Chughtai Lab provides a reliable screening mechanism to help clinicians differentiate Factor XIII deficiency from other bleeding disorders, facilitating targeted management plans such as Factor XIII concentrate replacement or fresh frozen plasma (FFP) administration.

Clinical Procedure: What to Expect

Patient Preparation

Appropriate patient preparation is essential to ensure the accuracy of coagulation testing and prevent pre-analytical errors. Patients undergoing the Urea Clot Lysis test at Chughtai Lab should observe the following guidelines:

• Medication History: Inform your prescribing physician and the laboratory staff of all medications you are currently taking, particularly anticoagulants such as heparin, warfarin, direct oral anticoagulants (DOACs), or aspirin, as these can interfere with clot formation and stability.
• Recent Transfusions: Disclose any recent blood or plasma transfusions, as donor blood contains active Factor XIII which can temporarily normalize test results and mask an underlying deficiency.
• Fasting: While strict fasting is generally not required for this specific test, it is advisable to avoid fatty meals immediately before sample collection to prevent lipemia, which can interfere with optical laboratory measurements.
• Hydration: Ensure you are well-hydrated by drinking adequate amounts of water prior to the blood draw, as this makes venipuncture easier and prevents hemoconcentration.

During the Procedure

The collection of the blood sample for the Urea Clot Lysis test is a standard venipuncture procedure performed by highly trained phlebotomists at Chughtai Lab. The process is designed to minimize patient discomfort and maintain sample integrity:

• Patient Positioning: You will be asked to sit comfortably in a phlebotomy chair or lie down. Your arm will be positioned to expose the antecubital fossa (the inner bend of the elbow).
• Sanitization: The phlebotomist will apply a tourniquet above the selected vein site to increase venous pressure and make the vein visible. The skin will be thoroughly cleansed with an antiseptic solution (usually 70% isopropyl alcohol) and allowed to air dry.
• Sample Collection: A sterile, single-use needle will be inserted into the vein. Blood is drawn directly into a light blue-top tube containing 3.2% buffered sodium citrate as an anticoagulant. The ratio of blood to anticoagulant (9:1) is critical for accurate coagulation testing.
• Post-Collection Care: Once the tube is filled to the correct volume, the needle is gently withdrawn, and immediate pressure is applied to the puncture site with a sterile gauze pad to prevent hematoma formation. A small bandage will be applied.
• Laboratory Processing: The collected blood sample is promptly transported to the laboratory, where it is centrifuged to obtain platelet-poor plasma. The plasma is clotted by adding calcium chloride or thrombin. The resulting clot is then suspended in a 5M urea solution and incubated at 37°C. The laboratory technologist monitors the clot at regular intervals (typically at 1, 2, 4, and 24 hours) to observe whether it remains intact or undergoes dissolution (lysis).

When is a Urea Clot Lysis (For Factor XIII Screening) Performed?

Evaluation of Unexplained Bleeding Diathesis

Physicians request a Urea Clot Lysis test when a patient exhibits significant clinical symptoms of a bleeding disorder, such as easy bruising, frequent nosebleeds, or prolonged bleeding after minor cuts, despite having completely normal results on routine coagulation screens (PT, aPTT, bleeding time, and platelet count). Because these standard tests do not evaluate the cross-linking phase of clot formation, the Urea Clot Lysis test is the primary screening tool used to investigate suspected distal pathway defects in the coagulation cascade.

Delayed Wound Healing and Tissue Repair

Factor XIII plays an essential role beyond coagulation; it is actively involved in tissue repair, cellular migration, and wound healing by cross-linking fibronectin and collagen. Patients with congenital or severe acquired Factor XIII deficiency often experience delayed wound healing, abnormal scar formation, or wound dehiscence (spontaneous reopening of surgical wounds). When a patient presents with chronic, non-healing wounds or post-operative wound complications without an obvious metabolic or infectious cause, clinicians order this test to rule out Factor XIII deficiency.

Umbilical Cord Bleeding in Newborns

Bleeding from the umbilical stump within the first few days of life is a classic, highly specific clinical presentation of congenital Factor XIII deficiency, occurring in up to 80% of affected individuals. If a newborn experiences persistent, unexplained bleeding from the umbilical site after birth, pediatricians urgently request the Urea Clot Lysis test. Early diagnosis in neonates is critical to initiating prophylactic therapy and preventing life-threatening complications such as intracranial hemorrhage.

Recurrent Spontaneous Abortions and Pregnancy Complications

Factor XIII is vital for the maintenance of pregnancy, as it facilitates the stable attachment of the cytotrophoblast to the uterine decidua and supports placental development. Women with undiagnosed Factor XIII deficiency frequently suffer from recurrent early spontaneous abortions, subchorionic hematomas, or severe deciduous bleeding. Obstetricians and hematologists recommend this screening test for women with a history of unexplained recurrent miscarriages to identify if a correctable coagulation defect is the underlying cause.

Intracranial Hemorrhage and Post-Traumatic Bleeding

Spontaneous or post-traumatic intracranial hemorrhage is the most severe and life-threatening manifestation of Factor XIII deficiency, affecting a significant percentage of untreated patients. Unlike other hemophilias where joint bleeding is most common, Factor XIII deficiency has a high propensity for central nervous system bleeding. If a patient presents with unexplained intracranial bleeding, or experiences delayed bleeding hours or days after a minor head trauma, this screening test is performed immediately to guide emergency therapeutic decisions.

What Does a Urea Clot Lysis (For Factor XIII Screening) Detect?

The Urea Clot Lysis test is highly sensitive to severe reductions in Factor XIII activity. It is designed to detect and assist in the clinical evaluation of several physiological states, pathological conditions, and diagnostic parameters:

• Severe congenital Factor XIII deficiency (activity levels typically below 1% to 2% of normal).
• Acquired Factor XIII deficiency secondary to severe hepatic dysfunction or liver cirrhosis.
• Presence of acquired Factor XIII inhibitors (autoantibodies) that neutralize active Factor XIII.
• Clot instability characterized by rapid dissolution in a 5M urea solution within 24 hours.
• Normal clot stability, where the fibrin clot remains completely intact after 24 hours of incubation.
• Increased risk of delayed post-operative hemorrhage in patients undergoing major surgical procedures.
• Potential underlying cause of neonatal umbilical stump bleeding.
• Etiology of abnormal wound healing, tissue repair failure, and weak scar tissue formation.
• Coagulation-related causes of recurrent spontaneous abortions and placental abruption.
• Risk factors for spontaneous soft tissue hematomas and muscle bleeds.
• Predisposition to life-threatening spontaneous intracranial hemorrhage.
• Distinction between primary hyperfibrinolysis and Factor XIII deficiency as causes of rapid clot breakdown.
• Consumption of Factor XIII during active episodes of Disseminated Intravascular Coagulation (DIC).
• Factor XIII depletion associated with severe inflammatory bowel disease (Crohn’s disease or Ulcerative Colitis).
• Decreased Factor XIII levels in patients undergoing intensive chemotherapy or suffering from leukemia.
• Efficacy of replacement therapy (such as Factor XIII concentrates or Cryoprecipitate) by assessing post-treatment clot stability.
• Involvement of Factor XIII in cases of unexplained hematuria or gastrointestinal bleeding.
• Clot solubility alterations caused by extreme hyperfibrinogenemia or severe hypofibrinogenemia.
• Interference in clot cross-linking caused by high concentrations of fibrin degradation products (FDPs).
• The necessity for advanced quantitative assays, such as chromogenic or ELISA-based Factor XIII activity tests, if the screening result is abnormal.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, we understand that timely diagnostic results are crucial for effective clinical decision-making and patient peace of mind. Because the Urea Clot Lysis test requires monitoring the clot over a continuous 24-hour incubation period to observe potential dissolution, the standard turnaround time for this test is typically 24 to 48 hours from the time of sample collection. This ensures that even slow-rate clot lysis is accurately captured and reported.

Once the analysis is complete, the findings are thoroughly reviewed and verified by our team of consultant hematologists and pathologists. Chughtai Lab offers multiple convenient ways to access your diagnostic reports. Patients can receive automated SMS notifications when their reports are ready. Reports can be viewed, downloaded, and printed directly from the official Chughtai Lab website or through the user-friendly Chughtai Lab mobile application. Additionally, physical copies of the reports can be collected from any of our numerous collection centers across Pakistan, or delivered directly to your home upon request.

Urea Clot Lysis Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Clot Stability in 5M Urea (at 24 hours)	Clot remains completely intact and undissolved after 24 hours of incubation.	Clot dissolves completely within 1 to 24 hours, indicating severe Factor XIII deficiency (<1-2% activity).
Clot Stability in 1% Monochloroacetic Acid	Clot remains stable and intact after 24 hours.	Rapid dissolution of the clot, confirming lack of covalent cross-linking.
Prothrombin Time (PT)	Normal (typically 11 to 13.5 seconds).	Normal (PT is unaffected by isolated Factor XIII deficiency).
Activated Partial Thromboplastin Time (aPTT)	Normal (typically 25 to 35 seconds).	Normal (aPTT is unaffected by isolated Factor XIII deficiency).
Thrombin Time (TT)	Normal (typically 12 to 14 seconds).	Normal (unless there is a concurrent fibrinogen abnormality).
Platelet Count	Normal (150,000 to 450,000/µL).	Normal (platelet count and function are independent of FXIII).
Fibrinogen Level	Normal (200 to 400 mg/dL).	Normal (severe hypofibrinogenemia can occasionally cause false-positive clot dissolution).
Clot Lysis with Normal Plasma Mix (1:1)	Not applicable in normal screening.	Correction of lysis (indicates factor deficiency); Failure to correct lysis (indicates presence of a Factor XIII inhibitor).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Urea Clot Lysis?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified consultant pathologists and hematologists who supervise all coagulation assays and ensure clinical accuracy.
• Patient-Focused Care: We prioritize patient comfort, safety, and convenience at every stage of the diagnostic journey, from sample collection to reporting.
• Quality Diagnostic Services: Chughtai Lab adheres to strict internal and external quality control protocols, maintaining international standards of diagnostic excellence.
• Professional Reporting: Our reports are comprehensive, clear, and structured to provide clinicians with the precise information needed for accurate diagnosis.
• Modern Diagnostic Approach: We utilize state-of-the-art laboratory equipment and standardized chemical assays to perform specialized tests like the Urea Clot Lysis.
• Comfortable Environment: Our collection centers across Pakistan are designed to provide a clean, sterile, and welcoming environment for all patients.
• Convenient Location: With an extensive network of diagnostic centers and home sample collection services, Chughtai Lab is easily accessible nationwide.
• Commitment to Accurate Diagnosis: We are dedicated to providing reliable, evidence-based diagnostic results that form the foundation of effective patient care.